Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06IAR
|
|||
| Former ID |
DAP000223
|
|||
| Drug Name |
Adenosine
|
|||
| Synonyms |
Adenosine, homopolymer; Adenine 9-beta-D-arabinofuranoside; Adenine-9-beta-D-ribofuranoside; Beta-D-Ribofuranoside, adenine-9; EA6C60C2-6AFB-4264-A2F0-541373DB950E; (2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol; 4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside; 6-Amino-9-.beta.-ribofuranosyl-9H-purine; 6-Amino-9-beta-D-ribofuranosyl-9H-purine; 6-Amino-9beta-D-ribofuranosyl-9H-purine; 9-(beta-D-Arabinofuranosyl)adenine; 9-beta-D-Ribofuranosidoadenine; 9-beta-D-Ribofuranosyl-9H-purin-6-amine; 9-beta-D-Ribofuranosyladenine; 9beta-D-Ribofuranosyladenine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Paroxysmal supraventricular tachycardia [ICD-11: BC81.Z] | Approved | [1], [2] | |
| Therapeutic Class |
Antiarrhythmic Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H13N5O4
|
|||
| Canonical SMILES |
C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)CO)O)O)N
|
|||
| InChI |
1S/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1
|
|||
| InChIKey |
OIRDTQYFTABQOQ-KQYNXXCUSA-N
|
|||
| CAS Number |
CAS 5536-17-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
2103, 3512, 584484, 584490, 585862, 586357, 597013, 819854, 821994, 823447, 825728, 826920, 828107, 828519, 829493, 830178, 830391, 833174, 833907, 836875, 837192, 855078, 855932, 3136392, 7847113, 7885717, 7978645, 8023217, 8024149, 8027268, 8143428, 8187141, 10318629, 11110168, 11120317, 11120805, 11121293, 11371396, 11484930, 11489073, 11490104, 11532406, 11532673, 11537606, 12090919, 14716094, 14774851, 14799162, 22394812, 24277685
|
|||
| ChEBI ID |
CHEBI:16335
|
|||
| ADReCS Drug ID | BADD_D00045 | |||
| SuperDrug ATC ID |
C01EB10
|
|||
| SuperDrug CAS ID |
cas=000058617
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A2b receptor (ADORA2B) | Target Info | Modulator | [3] |
| KEGG Pathway | Rap1 signaling pathway | |||
| Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Alcoholism | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| Pathwhiz Pathway | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
| Pathway Interaction Database | C-MYB transcription factor network | |||
| Reactome | Adenosine P1 receptors | |||
| G alpha (s) signalling events | ||||
| Surfactant metabolism | ||||
| WikiPathways | Nucleotide GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2844). | |||
| REF 2 | Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.